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A B S T R A C T
Since several years it has been accepted that persistent infection with certain (so called-high risk: HR) types of Human
papillomaviruses (HPV) represents a strong risk factor for cervical cancer. The most frequent HR HPV types 16 and 18
account for about 70% of this tumour, which is the second most frequent malignancy in women worldwide. Several stud-
ies in animal papillomavirus models revealed that protection against infection is conferred by neutralizing antibodies
directed against conformational epitopes of the major structural protein L1. Such antibodies can most efficiently be in-
duced by immunization with virus-like particles (VLP) that assemble spontaneously following expression of L1 in recom-
binant vectors. Large-scale production of HPV 16 and 18 VLPs proved to be successful facilitating, a few years ago, first
clinical trials on safety and immunogenicity. In the meantime more than 25,000 women have been included into several
efficacy trials which demonstrated protection against persistent infection with HPV 16 and 18 and against the develop-
ment of precursor lesions to cervical cancer. Although the ultimate proof of success, i.e. reduction of cancer incidence still
requires the immunization of large populations and many years of follow-up, the existing data are so persuasive that the
responsible agencies in several countries permitted the licensing of the first HPV vaccine in 2006. Several questions such
as the duration of protection, the need development of for post-exposure vaccination strategies and availability of such
vaccine in low-budget countries are open and will be discussed.
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Preventive vaccines are based on the induction of vi-
rus-neutralizing antibodies. For the papillomaviruses
this has first been achieved by immunization with forma-
lin-fixed wart extracts and subsequently by inactivated
purified viruses1. In demand of an appropriate infection
model, it was difficult to determine the neutralizing ac-
tivity of serum antibodies. The first in vitro assay for vi-
rus neutralization was the inhibition of focus formation
of mouse cells in culture by BPV virions2. A more sophis-
ticated neutralization assay was introduced by Kreider
and coworkers who grafted normal human tissue in-
fected in vitro with HPV 11 or HPV 16 under the renal
capsule of immuno-deficient mice where typical lesions
develop3. Infection is then monitored by phenotypic anal-
ysis and by HPV-specific RT-PCR. Only very recently, a
potentially high throughput neutralization assay on the
basis of pseudovirions containing a reported gene be-
came available which allows detection of neutralizing an-
tibodies in an in vitro setting4. Neutralizing antibodies
are directed against the major structural protein L1 and,
to a much lesser degree, against the minor capsid protein
L2. For induction of neutralizing antibodies, the L1 pro-
tein is required to be presented in a correctly folded
conformation. This became only possible with the pro-
duction of L1 virus-like particles (VLPs). In 1986 it had
already been shown that purified VP1 of mouse poly-
omavirus spontaneously assembles into virus-like parti-
cles5. This inspired in the early 1990s the production of
papillomavirus-like particles by different researchers. Zhou
and colleagues used a vaccinia virus expression system to
produce HPV 16 L1 VLPs, however the yield of this sys-
tem was extremely low and did not allow further charac-
terization of the antigen e.g. by immunological studies6.
Shortly after, it was demonstrated that HPV 1, BPV 1
and HPV 11 VLPs can be produced much more efficiently
compared to HPV 16 VLPs leading to the speculation
whether this might be due to intrinsic properties of the
L1 protein of different PV types7,8,9. After a report by
Kirnbauer and colleagues it became clear, however, that
the HPV 16 L1 gene of the original isolate by Dürst et al.
harboured a point mutation rendering its encoded L1
protein virtually assembly defective10. The HPV 16 pro-
totype genome, used by numerous researchers worldwide
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was derived from a tumour biopsy, in which the HPV 16
genome was integrated into the cellular genome and thus
had been without any selection pressure for the mainte-
nance of intact structural genes. When HPV 16 genomes
obtained from virus-producing lesions were analyzed,
the respective L1 proteins assembled with much greater
efficiency into VLPs. Sequence analysis revealed that
this difference was based on a single histidine to aspartic
acid exchange at position 202 of the HPV 16 L1 protein.
VLPs were subsequently produced successfully in insect
cells, later also in yeast, in plants and even in cell free
systems. Meanwhile, VLPs of several animal and human
papillomaviruses have been produced, i.e. cottontail rab-
bit papillomavirus, rabbit oral papillomavirus, BPV 1
and 4, canine oral papillomavirus and HPV types 1, 2, 6,
8, 11, 13, 16, 18, 31, 33, 39, 45, 58 and 5911,12,13–15, for re-
view see16. The production of VLPs in larger quantities
made structural and immunological studies possible.
The data obtained from several animal models fos-
tered the concept of prophylactic vaccines against HPV
infections. Virus-like particles proved to be prime candi-
dates for prophylactic vaccination since they induce high-
-titer conformational antibodies of neutralizing capacity
both in non-human primates and in man2,17–25. By pas-
sive transfer of IgG from immunized animals it was
shown that they confer protection against experimental
challenge26.
The first clinical trial with VLPs (of HPV 11) involv-
ing human subjects was initiated in 1996 (for reference
see Inglis et al.27). HPV 11 VLPs used in this study were
produced in insect cells. The success of this trial initiated
further HPV vaccine development. In several phase I
clinical trials safety and immunogenicity of HPV 11, 16
and 18-specific VLPs generated by expression of the L1
protein in yeast or in insect cells were demonstrat-
ed17,19,20–22. Three VLP-based vaccines (HPV 16, HPV 16
+ 18, HPV 6 + 11 + 16 + 18) were brought into clinical
efficacy trials. The so far only licensed vaccine provided
by Merck & Co (Gardasil
TM
) contains in addition to the
most relevant cancer-associated HPV types 16 and 18
also VLPs of the low-risk HPV types 6 and 11 aiming for
protection against genital warts whereas the product de-
veloped by GlaxoSmithKline has only the two high-risk
HPVs. The data obtained from immunization of about
25,000 young women receiving either vaccine or placebo
demonstrated after more than 4 years of follow-up pro-
tection against incident and persistent infection with
HPV 6/11, and/or HPV 16 an 18 and the lesions associ-
ated therewith (external genital lesions, high grade CIN,
adenocarcinoma in situ)28–32. Longer follow-up and large
scale population-based efficacy trials will be required to
evaluate the potential of these vaccines to reduce the in-
cidence of cervical cancer33,34. Based on the existing data,
however, the regulatory agencies in different countries
have approved. It will be more difficult to evaluate the ef-
ficacy towards genital warts since the information about
the incidence of this disease is rather scarce (http://
wrongdiagnosis.com/g/genital warts). The second prod-
uct manufactured by GlaxoSmithKline (consisting of HPV
16 + HPV 18 VLPs) is expected to enter the market soon.
After introduction of the vaccines there are several
open questions that can be solved only after wide applica-
tion in different countries and longer time of follow-up.
The critical issues include the acceptance of the HPV-
-specific vaccines within different cultures35,36 including
the question whether the vaccine will be marketed as
preventive measures against a sexually transmitted dis-
ease or as anti-cancer prophylaxis37. Other issues are the
duration of immune protection and the participation of
vaccinated women in Pap-screening programs since HPV
16 and 18 accounts for about 70% of cervical cancer
cases38 hence the risk for this disease by other high-risk
HPV types is not negligible. Therefore, vaccinated wo-
men need to be educated about the necessity to keep up
with the screening program although the intervals of the
visits can possibly be extended39. Obviously prophylactic
vaccination will be highly desirable in areas where scre-
ening programs are not offered to the general population
and where cervical cancer is a major public health prob-
lem. The high price clearly is prohibitive and joint efforts
of scientists (developing more cost effective protocols),
providers and politicians (discussing multi-tiered pric-
ing) and public and philanthropic foundations (providing
large amounts of money) are needed to make the vac-
cines available to the populations of highest need.
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RAZVOJ PROFILAKTI^KOG CJEPIVA PROTIV HPV-a
S A @ E T A K
Od prije nekoliko godina je prihva}ena tvrdnja da trajna infekcija s odre|enim (tzv. visokorizi~nim; HR od engl. high
risk) tipovima humanog papilomavirusa (HPV) predstavlja jaki faktor rizika za razvoj raka vrata maternice. Naj~e{}i
HR HPV-i su tipovi 16 i 18, povezani s oko 70% ovog tumora, koji je na drugom mjestu naj~e{}ih oboljenja kod `ena u
svijetu. Nekoliko studija na modelima animalnih papilomavirusa je pokazalo da je za{tita protiv ove infekcije neu-
traliziraju~ih antitijela protiv konformacijskih epitopa glavnog strukturnog proteina L1. Ta antitijela mogu biti vrlo
u~inkovito inducirana imunizacijom sa ~esticama sli~nim virusima (VLP, engl. Virus-Like Particles) koje se spontano
nakupljaju nakon ekspresije L1 u rekombinantnim vektorima. Velika skala proizvodnje VLP-ova od strane HPV 16 i 18
se pokazala uspje{nom, olak{avaju}i tako, prije nekoliko godina, prve klini~ke pokuse o sigurnosti i imunogenosti. U
me|uvremenu, vi{e od 25.000 `ena je bilo uklju~eno u nekoliko klini~kih pokusa o za{titi protiv trajne infekcije ti-
povima HPV-a 16 i 18 te o sprje~avanju razvoja o{te}enja koja prethode raku vrata maternice. Iako je krajnji dokaz
uspjeha smanjenje stope pojavnosti raka, potrebno je jo{ cijepiti velike skupine te ih godinama pratiti. Ipak, sada{nji
podaci su toliko uvjerljivi da su zadu`ene agencije u nekoliko zemalja dopustile uvo|enje prvog cjepiva protiv HPV-a u
2006. g. Neka pitanja, kao {to je trajanje za{tite, potreba za razvojem strategija nakon cijepljenja i dostupnost ovog
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